Boiron SA (0DTF.L)
EUR 27.0
(-0.37%)
EUR 27.0
(-0.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.7 Million EUR | -38.18% |
| 2022 | 22.16 Million EUR | 75.84% |
| 2021 | 12.6 Million EUR | 1.42% |
| 2020 | 12.43 Million EUR | -4.5% |
| 2019 | 13.01 Million EUR | 117.22% |
| 2018 | 5.99 Million EUR | -62.49% |
| 2017 | 15.97 Million EUR | 72.63% |
| 2016 | 9.25 Million EUR | 5.33% |
| 2015 | 8.78 Million EUR | -10.86% |
| 2014 | 9.85 Million EUR | 85.93% |
| 2013 | 5.3 Million EUR | -7.78% |
| 2012 | 5.74 Million EUR | 11.24% |
| 2011 | 5.16 Million EUR | -26.55% |
| 2010 | 7.03 Million EUR | 24.34% |
| 2009 | 5.65 Million EUR | 53.37% |
| 2008 | 3.68 Million EUR | -59.38% |
| 2007 | 9.08 Million EUR | -59.87% |
| 2006 | 22.63 Million EUR | -17.85% |
| 2005 | 27.55 Million EUR | 514.02% |
| 2004 | 4.48 Million EUR | -17.99% |
| 2003 | 5.47 Million EUR | 14.17% |
| 2002 | 4.79 Million EUR | 4.88% |
| 2001 | 4.56 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.03 Million EUR | 0.0% |
| 2023 Q2 | 12.68 Million EUR | 0.0% |
| 2023 Q4 | 13.7 Million EUR | 0.0% |
| 2023 FY | 13.7 Million EUR | -38.18% |
| 2022 FY | 22.16 Million EUR | 75.84% |
| 2022 Q4 | 22.16 Million EUR | 0.0% |
| 2022 Q2 | 25.27 Million EUR | 0.0% |
| 2021 Q4 | 12.6 Million EUR | 0.0% |
| 2021 Q2 | 10.43 Million EUR | 0.0% |
| 2021 FY | 12.6 Million EUR | 1.42% |
| 2020 FY | 12.43 Million EUR | -4.5% |
| 2020 Q2 | 10.65 Million EUR | 0.0% |
| 2020 Q4 | 12.43 Million EUR | 0.0% |
| 2019 Q2 | 14.89 Million EUR | 0.0% |
| 2019 Q4 | 13.01 Million EUR | 0.0% |
| 2019 FY | 13.01 Million EUR | 117.22% |
| 2018 Q2 | 10.08 Million EUR | 0.0% |
| 2018 Q4 | 5.99 Million EUR | 0.0% |
| 2018 FY | 5.99 Million EUR | -62.49% |
| 2017 Q4 | 15.97 Million EUR | 0.0% |
| 2017 FY | 15.97 Million EUR | 72.63% |
| 2017 Q2 | 11.31 Million EUR | 0.0% |
| 2016 FY | 9.25 Million EUR | 5.33% |
| 2016 Q4 | 9.25 Million EUR | 0.0% |
| 2016 Q2 | 8.47 Million EUR | 0.0% |
| 2015 Q4 | 8.78 Million EUR | 0.0% |
| 2015 Q2 | 8.73 Million EUR | 0.0% |
| 2015 FY | 8.78 Million EUR | -10.86% |
| 2014 Q4 | 9.85 Million EUR | 0.0% |
| 2014 FY | 9.85 Million EUR | 85.93% |
| 2014 Q2 | 8.93 Million EUR | 0.0% |
| 2013 Q2 | 6.77 Million EUR | 0.0% |
| 2013 Q4 | 5.3 Million EUR | 0.0% |
| 2013 FY | 5.3 Million EUR | -7.78% |
| 2012 Q2 | 5.14 Million EUR | 0.0% |
| 2012 Q1 | - EUR | -100.0% |
| 2012 Q4 | 5.74 Million EUR | 0.0% |
| 2012 FY | 5.74 Million EUR | 11.24% |
| 2012 Q3 | - EUR | -100.0% |
| 2011 Q2 | 8.24 Million EUR | 0.0% |
| 2011 FY | 5.16 Million EUR | -26.55% |
| 2011 Q4 | 5.16 Million EUR | 0.0% |
| 2010 Q4 | 7.03 Million EUR | 0.0% |
| 2010 FY | 7.03 Million EUR | 24.34% |
| 2010 Q2 | 8.16 Million EUR | 0.0% |
| 2009 Q4 | 5.65 Million EUR | 0.0% |
| 2009 FY | 5.65 Million EUR | 53.37% |
| 2008 FY | 3.68 Million EUR | -59.38% |
| 2007 FY | 9.08 Million EUR | -59.87% |
| 2006 FY | 22.63 Million EUR | -17.85% |
| 2005 FY | 27.55 Million EUR | 514.02% |
| 2004 FY | 4.48 Million EUR | -17.99% |
| 2003 FY | 5.47 Million EUR | 14.17% |
| 2002 FY | 4.79 Million EUR | 4.88% |
| 2001 FY | 4.56 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Laboratorios Farmaceuticos Rovi, S.A. | 46.63 Million EUR | 70.619% |
| Vetoquinol SA | 17.62 Million EUR | 22.271% |
| Valneva SE | 208.81 Million EUR | 93.438% |
| AB Science S.A. | 19.1 Million EUR | 28.266% |
| Nanobiotix S.A. | 45.48 Million EUR | 69.874% |
| PHAXIAM Therapeutics S.A. | 10.19 Million EUR | -34.347% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -35957.895% |
| BioSenic S.A. | 28.16 Million EUR | 51.344% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 75.296% |
| Formycon AG | 29.48 Million EUR | 53.53% |